Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

Item
http://www.wikidata.org/entity/Q36247606
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma.Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Light of DNA-alkylating agents in castration-resistant prostate cancer cells: a novel mixed EGFR/DNA targeting combi-molecule.Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advancedThe PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
P2860

Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

Item
http://www.wikidata.org/entity/Q36247606
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Epigenetic modifiers enhance t ...... agents in lymphoma cell lines.
@ast
Epigenetic modifiers enhance t ...... agents in lymphoma cell lines.
@en
type
label
Epigenetic modifiers enhance t ...... agents in lymphoma cell lines.
@ast
Epigenetic modifiers enhance t ...... agents in lymphoma cell lines.
@en
prefLabel
Epigenetic modifiers enhance t ...... agents in lymphoma cell lines.
@ast
Epigenetic modifiers enhance t ...... agents in lymphoma cell lines.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Epigenetic modifiers enhance t ...... agents in lymphoma cell lines.
@en
P2093
P2860
P304
P31
P356
10.1016/J.EXPHEM.2012.06.001
P433
P478
P577
P5875
P698
P921
P932